文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
M. McHenry
发表
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
N. Agarwal, C. Drake, H. Scher, 2014, The Lancet. Oncology.
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
C. Porta, T. Powles, R. Motzer, 2020 .